230 related articles for article (PubMed ID: 9892196)
1. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
[TBL] [Abstract][Full Text] [Related]
2. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Holland SK; Bergman AM; Zhao Y; Adams ER; Pizzorno G
Magn Reson Med; 1997 Dec; 38(6):907-16. PubMed ID: 9402191
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.
Spector T; Cao S; Rustum YM; Harrington JA; Porter DJ
Cancer Res; 1995 Mar; 55(6):1239-41. PubMed ID: 7882316
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
6. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Baccanari DP; Davis ST; Knick VC; Spector T
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11064-8. PubMed ID: 8248211
[TBL] [Abstract][Full Text] [Related]
7. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
Harada M; Nishitani H; Shirahama T; Koga K; Miura I
Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
[TBL] [Abstract][Full Text] [Related]
8. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.
Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H
Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086
[TBL] [Abstract][Full Text] [Related]
9. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
10. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
11. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
12. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
16. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.
Aboagye EO; Saleem A; Cunningham VJ; Osman S; Price PM
Cancer Res; 2001 Jul; 61(13):4937-41. PubMed ID: 11431319
[TBL] [Abstract][Full Text] [Related]
17. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.
Arellano M; Malet-Martino M; Martino R; Spector T
Br J Cancer; 1997; 76(9):1170-80. PubMed ID: 9365165
[TBL] [Abstract][Full Text] [Related]
18. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
Diasio RB
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
[TBL] [Abstract][Full Text] [Related]
19. Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys.
Holstege A; Pausch J; Gerok W
Cancer Res; 1986 Nov; 46(11):5576-81. PubMed ID: 3756903
[TBL] [Abstract][Full Text] [Related]
20. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]